Take Home Regulation Page 4098

Page 4098

Federal Register

Vol. 66, No. 11 / Wednesday, January 17, 2001 / Rules and Regulations

(i) Unsupervised or “take-home” use.

To limit the potential for diversion of opioid agonist treatment medications to the illicit market, opioid agonist treatment medications dispensed to patients for unsupervised use shall be subject to the following requirements.

(1) Any patient in comprehensive maintenance treatment may receive a single take-home dose for a day that the clinic is closed for business, including Sundays and State and Federal holidays.

(2) Treatment program decisions on dispensing opioid treatment medications to patients for unsupervised use beyond that set forth in paragraph (i)(1) of this section, shall be determined by the medical director.

  1. Absence of recent abuse of drugs (opioid or nonnarcotic),

    including alcohol;

  2. Regularity of clinic attendance;
  3. Absence of serious behavioral problems at the clinic;
  4. Absence of known recent criminal activity, e.g., drug dealing;
  5. Stability of the patient’s home environment and social relationships;
  6. Length of time in comprehensive maintenance treatment;
  7. Assurance that take-home medication can be safely stored within the patient’s home; and
  8. Whether the rehabilitative benefit the patient derived from decreasing the frequency of clinic attendance outweighs the potential risks of diversion.

(3) Such determinations and the basis for such determinations consistent with the criteria outlined in paragraph (i)(2) of this section shall be documented in the patient’s medical record. If it is determined that a patient is responsible in handling opioid drugs, the following restrictions apply:

  1. During the first 90 days of treatment, the take-home Supply (beyond that of paragraph (i)(1) of this section) is limited to a single dose each week and the patient shall ingest all other doses under appropriate supervision as provided for under the regulations in this subpart.
  2. In the second 90 days of treatment, the take-home Supply (beyond that of paragraph (i)(1) of this section) is two doses per week.
  3. In the third 90 days of treatment, the take-home supply (beyond that of paragraph (i)(1) of this section) is three doses per week.
  4. In the remaining months of the first year, a patient may be given a maximum 6-day supply of take-home medication.
  5. After 1 year of continuous treatment, a patient may be given a maximum 2-week supply of take-home medication.
  6. After 2 years of continuous treatment, a patient may be given a maximum one-month supply of take-home medication, but must make monthly visits.

(4) No medications shall be dispensed to patients in short-term detoxification treatment or interim maintenance treatment for unsupervised or take-home use.

Similar Posts

  • TRIPS Update

    Admin 08/29/2021

    TRIPS No Longer Operating This past Spring TRIPS the project that assists methadone patients to find an alternative site while traveling was closed. It happened very quickly and as you would expect created problems immediately. NAMA began receiving calls as early as March from patients trying to locate a program in the area that they…

  • Find Treatment

    Admin 04/21/2021

    Find Select or search by facility name Near Radius: 15 miles Suggested Filters CCAPPCCAPP EducationOnline EducationRecovery Residences (Sober Living)65+Treatment CenterShowersMedicaidUnder 18Addiction and SUD ServicesMental Health ServicesRecovery Organizations (RO)CCAPP SchoolCCAPP Recovery Residences Don’t see your facility?Click here to get listed Available beds at this house Weingart Center – San Pedro Street Los Angeles CA, 90013 100…

  • DRAFT

    Admin 06/23/2022

    Model Policy Guidelines for Opioid Addiction Treatment in the Medical Office Draft approved for distribution July 2001 THE FEDERATION OF STATE MEDICAL BOARDS OF THE UNITED STATES, INC. Introduction On October 17, 2000, “The Children’s Health Act of 2000” (HR 4365) was signed into federal law. Section 3502 of that Act sets forth the “Drug…

  • Registration for the 2022 CMA Training Course is now open!

    Admin 06/20/2022

    The 2022 Certified Medication Assisted Treatment Advocate (CMA) Course will be held as a Pre-Conference Session of the 2022 AATOD Conference on:Sunday, October 30, 20229:00am – 5:00pmHilton Baltimore Inner Harbor401 W. Pratt StreetBaltimore, MD 21201We encourage all supporters of MAT, patient and non-patient, to become Certified MAT Advocates so that all energies directed toward the…

  • Click Page!

    Admin 04/11/2023

    How to use the Click Page The Click Page helps NAMA earn money. Clicking on a banner can earn from $.05 to $1 or more. All you have to do is go down the page and click on each banner. A window will open, wait a few seconds and then close it. You will find…

  • NAMA Recovery Advocate

    Admin 11/22/2022

    April 2012 CONTENTS NAMA-Recovery Petition Site has Amassed over 3800 Signatures and 1st Person Testimonials Regarding Methadone Treatments Life-Saving Effects. Methadone Treatment Under Pressure in Many Jurisdictions, but Nowhere as Critical as the British Isles. (Conservative Government releases Putting Recovery First — a Roadmap for the Elimination of MAT and Full Implementation of Abstinance Based…